21 results on '"Ribaudo, Heather J"'
Search Results
2. Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.
- Author
-
Fichtenbaum, Carl J, Ribaudo, Heather J, Leon-Cruz, Jorge, Overton, Edgar T, Zanni, Markella V, Malvestutto, Carlos D, Aberg, Judith A, Kileel, Emma M, Fitch, Kathleen V, Schalkwyk, Marije Van, Kumarasamy, Nagalingeswaran, Martinez, Esteban, Santos, Breno Riegel, Joseph, Yvetot, Lo, Janet, Siminski, Sue, Melbourne, Kathleen, Sponseller, Craig A, Desvigne-Nickens, Patrice, and Bloomfield, Gerald S
- Subjects
- *
ANTIRETROVIRAL agents , *CD4 lymphocyte count , *CLINICAL trial registries , *BODY mass index , *LOGISTIC regression analysis - Abstract
Background: Patterns of antiretroviral therapy (ART) use and immunologic correlates vary globally, and contemporary trends are not well described.Methods: The REPRIEVE trial (Randomized Trial to Prevent Vascular Events in HIV) enrolled persons with human immunodeficiency virus (HIV) who were aged 40-75 years, receiving ART, and had low-to-moderate cardiovascular disease risk. ART use was summarized within Global Burden of Disease (GBD) super-regions, with adjusted linear and logistic regression analyses examining associations with immune parameters and key demographics.Results: A total of 7770 participants were enrolled, with a median age of 50 years (interquartile range, 45-55 years); 31% were female, 43% were black or African American, 15% were Asian, 56% had a body mass index >25 (calculated as weight in kilograms divided by height in meters squared), and 49% were current or former smokers. The median CD4 T-cell count was 620/µL (interquartile range, 447-826/ µ L), and the median duration of prior ART use, 9.5 years (5.3-14.8) years. The most common ART regimens were nucleoside/nucleotide reverse-transcriptase inhibitor (NRTI) plus nonnucleoside reverse-transcriptase inhibitor (43%), NRTI plus integrase strand transfer inhibitor (25%), and NRTI plus protease inhibitor (19%). Entry ART varied by GBD region, with shifts during the trial enrollment period. In adjusted analyses, entry CD4 cell count and CD4/CD8 ratio were associated with GBD region, sex, entry regimen, duration of ART, and nadir CD4 cell count; CD4 and CD8 cell counts were also associated with body mass index and smoking status.Conclusions: There were substantial variations in ART use by geographic region and over time, likely reflecting the local availability of specific medications, changes in treatment guidelines and provider/patient preferences. The analyses of CD4 cell counts and CD4/CD8 ratios may provide valuable insights regarding immune correlates and outcomes in people living with HIV.Clinical Trials Registration: NCT02344290. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
3. Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators.
- Author
-
Grinspoon, Steven K, Douglas, Pamela S, Hoffmann, Udo, and Ribaudo, Heather J
- Subjects
CARDIOVASCULAR diseases ,HIV ,PREVENTIVE medicine ,COMORBIDITY ,ANTIRETROVIRAL agents - Abstract
The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 participants from 2015 to 2019 with sites across 5 continents, REPRIEVE will assess the effects of a statin as a cardiovascular disease prevention strategy in people with HIV (PWH) receiving antiretroviral therapy (ART). Although the primary purpose of REPRIEVE, and its substudy assessing coronary plaque, is to assess cardiovascular outcomes, the trial is a rich source of data on population characteristics and critical comorbidities in PWH, particularly across Global Burden of Disease (GBD) regions, reflective of the ethnic, racial, and gender diversity in this global epidemic. The purpose of this Supplement is to leverage the rich phenotyping in REPRIEVE, to provide data on detailed patterns of baseline ART and immune function by GBD region, reproductive aging among cisgender women, and data on the participation and clinical characteristics of transgender participants. We also leveraged REPRIEVE to assess critical comorbidities, including renal dysfunction, muscle function and frailty, and myocardial steatosis. REPRIEVE is a remarkable collaboration between funders, trial networks, clinical research sites, clinical and data coordinating centers, and willing participants who devoted their time to make the trial possible. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection.
- Author
-
Dubé, Michael P, Chan, Ellen S, Lake, Jordan E, Williams, Brett, Kinslow, Jennifer, Landay, Alan, Coombs, Robert W, Floris-Moore, Michelle, Ribaudo, Heather J, and Yarasheski, Kevin E
- Subjects
INFLAMMATION prevention ,ANTIGENS ,BIOMARKERS ,BLACK people ,DRUG tolerance ,HISPANIC Americans ,HIV infections ,HIV-positive persons ,IMMUNE system ,INFLAMMATORY mediators ,MEDICAL protocols ,MONOCYTES ,WHITE people ,CD4 antigen ,VIRAL load ,ANTIRETROVIRAL agents ,RANDOMIZED controlled trials ,BLIND experiment ,CD4 lymphocyte count ,PHARMACODYNAMICS ,SITAGLIPTIN ,THERAPEUTICS - Abstract
Background Dipeptidyl peptidase-4 (DPP-4) inhibitors have pleotropic anti-inflammatory and immune regulatory effects in addition to glucoregulation. We evaluated inflammation and immune markers in suppressed human immunodeficiency virus (HIV) infection during treatment with the DPP-4 inhibitor sitagliptin. Methods Virologically suppressed adults with HIV without diabetes on stable antiretroviral therapy (ART) with ≥100/μL CD4 cells were randomized to 16 weeks of sitagliptin 100 mg/day vs placebo in a multicenter trial. The primary endpoint was the change in plasma soluble CD14 (sCD14) from baseline to week 15–16. Results Ninety participants were randomized, and 42 from each arm were included in per-protocol analyses. Participants were 45% non-Hispanic white, 38% non-Hispanic black, and 15% Hispanic, with a median age of 51 years; 83% were male; and the median CD4 count was 602 cells/μL. At week 15–16, there was no difference in sCD14 change between the 2 arms (P =.69). Relative to placebo, the sitagliptin arm had 47% greater decline in CXCL10 (95% confidence interval, –57% to –35%) at week 15 (P <.001). There were no significant between-arm differences in other soluble biomarkers, total CD4 and CD8 counts, or markers of lymphocyte or monocyte activation. Sitagliptin was well tolerated. Conclusions Sixteen weeks of sitagliptin had no effect on sCD14 levels in virologically suppressed participants with HIV. CXCL10, a chemokine involved in atherogenesis that predicts non-AIDS events during ART, declined markedly with sitagliptin. This suggests that DPP-4 inhibition has the potential to reduce cardiovascular morbidity in treated HIV infection. Clinical Trials Registration NCT01426438. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial.
- Author
-
Gandhi, Monica, Horng, Howard, Phung, Nhi, Kuncze, Karen, Bacchetti, Peter, Jin, Chengshi, Ofokotun, Igho, Sheth, Anandi N, Lennox, Jeffrey, Ribaudo, Heather J, Haas, David W, Okochi, Hideaki, Landovitz, Raphael J, and Currier, Judith S
- Subjects
ANTIRETROVIRAL agents ,HIV infections ,LONGITUDINAL method ,MEDICAL protocols ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,HAIR analysis - Abstract
Concentrations of antiretrovirals in hair are associated with virologic outcomes in cohorts of human immunodeficiency virus (HIV)-positive individuals but have never been examined in a clinical trial. We show for the first time the predictive utility of hair antiretroviral concentrations in a large HIV treatment-naive trial (AIDS Clinical Trials Group protocol A5257). [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
- Author
-
Brown, Todd T., Moser, Carlee, Currier, Judith S., Ribaudo, Heather J., Rothenberg, Jennifer, Kelesidis, Theodoros, Otto Yang, Dubé, Michael P., Murphy, Robert L., Stein, James H., McComsey, Grace A., and Yang, Otto
- Subjects
BONE density ,ANTIRETROVIRAL agents ,TENOFOVIR ,BISOPROLOL ,EMTRICITABINE ,ATAZANAVIR ,RITONAVIR ,PROTEASE inhibitors ,COMBINATION drug therapy ,HIV ,HIV infections ,RESEARCH methodology ,RESEARCH funding ,STATISTICAL sampling ,VIRAL load ,RANDOMIZED controlled trials ,ANTI-HIV agents ,HIV integrase inhibitors ,HIV protease inhibitors ,REVERSE transcriptase inhibitors ,THERAPEUTICS - Abstract
Background: Specific antiretroviral therapy (ART) medications and the severity of human immunodeficiency virus (HIV) disease before treatment contribute to bone mineral density (BMD) loss after ART initiation.Methods: We compared the percentage change in BMD over 96 weeks in 328 HIV-infected, treatment-naive individuals randomized equally to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or raltegravir (RAL). We also determined whether baseline levels of inflammation markers and immune activation were independently associated with BMD loss.Results: At week 96, the mean percentage changes from baseline in spine and hip BMDs were similar in the protease inhibitor (PI) arms (spine: -4.0% in the ATV/r group vs -3.6% in the DRV/r [P = .42]; hip: -3.9% in the ATV/r group vs -3.4% in the DRV/r group [P = .36]) but were greater in the combined PI arms than in the RAL arm (spine: -3.8% vs -1.8% [P < .001]; hip: -3.7% vs -2.4% [P = .005]). In multivariable analyses, higher baseline concentrations of high-sensitivity C-reactive protein, interleukin 6, and soluble CD14 were associated with greater total hip BMD loss, whereas markers of CD4(+) T-cell senescence and exhaustion (CD4(+)CD28(-)CD57(+)PD1(+)) and CD4(+) T-cell activation (CD4(+)CD38(+)HLA-DR(+)) were associated with lumbar spine BMD loss.Conclusions: BMD losses 96 weeks after ART initiation were similar in magnitude among patients receiving PIs, ATV/r, or DRV/r but lowest among those receiving RAL. Inflammation and immune activation/senescence before ART initiation independently predicted subsequent BMD loss. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
7. Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation.
- Author
-
Turner Overton, Edgar, Chan, Ellen S., Brown, Todd T., Tebas, Pablo, McComsey, Grace A., Melbourne, Kathleen M., Napoli, Andrew, Hardin, William Royce, Ribaudo, Heather J., and Yin, Michael T.
- Subjects
ANTIRETROVIRAL agents ,BONE densitometry ,PHYSIOLOGICAL effects of calcium ,PHYSIOLOGICAL effects of vitamin D ,DIAGNOSIS of bone diseases ,TENOFOVIR ,HIV infections ,THERAPEUTICS - Abstract
Background: Antiretroviral therapy initiation for HIV-1 infection is associated with 2% to 6% loss of bone mineral density (BMD). Objective: To evaluate the effect of vitamin D
3 plus calcium supplementation on bone loss associated with antiretroviral therapy initiation. Design: 48-week prospective, randomized, double-blind, placebo-controlled study. (ClinicalTrials.gov: NCT01403051) Setting: 39 AIDS Clinical Trials Group units. Patients: Adults with antiretroviral therapy-naive HIV. Measurements: BMD by dual-energy x-ray absorptiometry, 25- hydroxyvitamin D levels, and other laboratory assessments. Results: 165 eligible patients were randomly assigned (79 received vitamin D3 plus calcium and 86 received placebo). The study groups were well-balanced at baseline: 90% were men, 33% were non-Hispanic black, and the median CD4 count was 0.341 x 109 cells/L. At 48 weeks, the percentage of decline in total hip BMD was smaller in the vitamin D3 plus calcium group than in the placebo group: Medians were —1.36% (interquartile range [IQR], -3.43% to 0.50%) and -3.22% (IQR, -5.56% to -0.88%), respectively (P = 0.004). Similar results were seen at the lumbar spine. At 48 weeks, 90% of patients achieved HIV-1 RNA levels less than 50 copies/mL. Levels of 25-hydroxyvitamin D3 increased with vitamin D3 plus calcium but not with placebo: Median change was 61.2 nmol/L (IQR, 36.4 to 94.3) versus 1.7 nmol/L (IQR, -13.2 to 10.7) (P< 0.001). Overall, 103 patients (62%) reported 1 or more adverse event, with similar distribution between groups; no cases of hypercalcemia and 1 case of nephrolithiasis were reported in the placebo group. Limitation: No international sites were included, and follow-up was only 48 weeks. Conclusion: Vitamin D3 plus calcium supplementation mitigates the BMD loss seen with initiation of efavirenz/emtricitabine/tenofovir disoproxil fumarate. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
8. Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1.
- Author
-
Lennox, Jeffrey L., Landovitz, Raphael J., Ribaudo, Heather J., Ofotokun, Ighovwerha, Na, Lumine H., Godfrey, Catherine, Kuritzkes, Daniel R., Sagar, Manish, Brown, Todd T., Cohn, Susan E., McComsey, Grace A., Aweeka, Francesca, Fichtenbaum, Carl J., Presti, Rachel M., Koletar, Susan L., Haas, David W., Patterson, Kristine B., Benson, Constance A., Baugh, Bryan P., and Leavitt, Randi Y.
- Subjects
REVERSE transcriptase inhibitors ,ANTIRETROVIRAL agents ,THERAPEUTICS ,HIV infections ,HIV-positive persons ,ATAZANAVIR ,RALTEGRAVIR - Abstract
Background: Nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy is not suitable for all treatment-naive HIV-infected persons. Objective: To evaluate 3 nonnucleoside reverse transcriptase inhibitor-sparing initial antiretroviral regimens to show equivalence for virologic efficacy and tolerability. Design: A phase 3, open-label study randomized in a 1:1:1 ratio with follow-up for at least 96 weeks. (ClinicalTrials.gov: NCT00811954) Setting: 57 sites in the United States and Puerto Rico. Patients: Treatment-naive persons aged 18 years or older with HIV-1 RNA levels greater than 1000 copies/mL without resistance to nucleoside reverse transcriptase inhibitors or protease inhibitors. Intervention: Atazanavir, 300 mg/d, with ritonavir, 100 mg/d; raltegravir, 400 mg twice daily; or darunavir, 800 mg/d, with ritonavir, 100 mg/d, plus combination emtricitabine, 200 mg/d, and tenofovir disoproxil fumarate, 300 mg/d. Measurements: Virologic failure, defined as a confirmed HIV-1 RNA level greater than 1000 copies/mL at or after 16 weeks and before 24 weeks or greater than 200 copies/mL at or after 24 weeks, and tolerability failure, defined as discontinuation of atazanavir, raltegravir, or darunavir for toxicity. A secondary end point was a combination of virologic efficacy and tolerability. Results: Among 1809 participants, all pairwise comparisons of incidence of virologic failure over 96 weeks showed equivalence within a margin of equivalence defined as -10 % to 10%. Raltegravir and ritonavir-boosted darunavir were equivalent for tolerability, whereas ritonavir-boosted atazanavir resulted in a 12.7% and 9.2% higher incidence of tolerability discontinuation than raltegravir and ritonavir-boosted darunavir, respectively, primarily because of hyperbilirubinemia. For combined virologic efficacy and tolerability, ritonavir-boosted darunavir was superior to ritonavir-boosted atazanavir, and raltegravir was superior to both protease inhibitors. Antiretroviral resistance at the time of virologic failure was rare but more frequent with raltegravir. Limitation: The trial was open-label, and ritonavir was not provided. Conclusion: Over 2 years, all 3 regimens attained high and equivalent rates of virologic control. Tolerability of regimens containing raltegravir or ritonavir-boosted darunavir was superior to that of the ritonavir-boosted atazanavir regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Racial Differences in Response to Antiretroviral Therapy for HIV Infection: An AIDS Clinical Trials Group (ACTG) Study Analysis.
- Author
-
Ribaudo, Heather J., Smith, Kimberly Y., Robbins, Gregory K., Flexner, Charles, Haubrich, Richard, Chen, Yun, Fischl, Margaret A., Schackman, Bruce R., Riddler, Sharon A., and Gulick, Roy M.
- Subjects
- *
ANTIRETROVIRAL agents , *THERAPEUTICS , *HIV infections , *VIROLOGY , *CLINICAL trials , *AIDS , *SCIENTIFIC observation , *SOCIAL factors - Abstract
Blacks had a 40% higher risk of virologic failure on initial antiretroviral therapy compared to whites. This observation was consistent over a broad range of regimens, suggesting it may be driven by unmeasured social factors; biological factors cannot be ruled out.Background. In the United States, black individuals infected with human immunodeficiency virus (HIV) have higher rates of virologic failure on antiretroviral therapy (ART) and of death compared to white individuals. The cause for these disparities is uncertain. We sought to examine differences in virologic outcomes among antiretroviral-naive clinical trial participants starting randomized ART and to investigate factors to explain the differences.Methods. Individual-level data from participants initiating ART in 5 AIDS Clinical Trials Group studies were analyzed. Included studies were those conducted during 1998–2006 with a primary outcome of virologic failure. The primary outcome measure was time to virologic failure, regardless of ART changes.Results. A total of 2495 individuals (1151 black; 1344 white) were included with a median follow-up of 129 weeks. Compared to whites, blacks had an increased hazard of virologic failure (hazard ratio [HR]; 1.7; 95% confidence interval [CI], 1.4–1.9; P < .001), with no evidence of heterogeneity across regimens (P = .97); the association remained after adjustment for measured confounders (HR, 1.4; 95% CI, 1.2–1.6; P < .001). Increased hazard of virologic failure was associated with younger age, higher pretreatment HIV type 1 RNA level, lower pretreatment CD4 cell count, hepatitis C antibody, less education, and recent nonadherence to treatment. Sensitivity analyses with different endpoint definitions demonstrated similar results.Conclusions. In this analysis, blacks had a 40% higher virologic failure risk than whites that was not explained by measured confounders. The observation was consistent over a range of regimens, suggesting that the difference may be driven by social factors; however, biological factors cannot be ruled out. Further research should identify the sources of racial disparities and develop strategies to reduce them. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. Highly Active Antiretroviral Therapy and Adverse Birth Outcomes Among HIV-Infected Women in Botswana.
- Author
-
Chen, Jennifer Y., Ribaudo, Heather J., Souda, Sajini, Parekh, Natasha, Ogwu, Anthony, Lockman, Shahin, Powis, Kathleen, Dryden-Peterson, Scott, Creek, Tracy, Jimbo, William, Madidimalo, Tebogo, Makhema, Joseph, Essex, Max, and Shapiro, Roger L
- Subjects
- *
ANTIRETROVIRAL agents , *DRUG side effects , *TREATMENT effectiveness , *THERAPEUTICS , *HIV infections , *PREGNANCY , *AIDS in women , *CHILDBIRTH - Abstract
Background. It is unknown whether adverse birth outcomes are associated with maternal highly active antiretroviral therapy (HAART) in pregnancy, particularly in resource-limited settings.Methods. We abstracted obstetrical records at 6 sites in Botswana for 24 months. Outcomes included stillbirths (SBs), preterm delivery (PTD), small for gestational age (SGA), and neonatal death (NND). Among human immunodeficiency virus (HIV)–infected women, comparisons were limited to HAART exposure status at conception, and those with similar opportunities for outcomes. Comparisons were adjusted for CD4+ lymphocyte cell count.Results. Of 33 148 women, 32 113 (97%) were tested for HIV, of whom 9504 (30%) were HIV infected. Maternal HIV was significantly associated with SB, PTD, SGA, and NND. Compared with all other HIV-infected women, those continuing HAART from before pregnancy had higher odds of PTD (adjusted odds ratio [AOR], 1.2; 95% confidence interval [CI], 1.1, 1.4), SGA (AOR, 1.8; 95% CI, 1.6, 2.1) and SB (AOR, 1.5; 95% CI, 1.2, 1.8). Among women initiating antiretroviral therapy in pregnancy, HAART use (vs zidovudine) was associated with higher odds of PTD (AOR, 1.4; 95% CI, 1.2, 1.8), SGA (AOR, 1.5; 95% CI, 1.2, 1.9), and SB (AOR, 2.5; 95% CI, 1.6, 3.9). Low CD4+ was independently associated with SB and SGA, and maternal hypertension during pregnancy with PTD, SGA, and SB.Conclusions. HAART receipt during pregnancy was associated with increased PTD, SGA, and SB. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
11. Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure: A Systematic Review and Pooled Analysis.
- Author
-
Li, Jonathan Z., Paredes, Roger, Ribaudo, Heather J., Svarovskaia, Evguenia S., Metzner, Karin J., Kozal, Michael J., Hullsiek, Kathy Huppler, Balduin, Melanie, Jakobsen, Martin R., Geretti, Anna Maria, Thiebaut, Rodolphe, Ostergaard, Lars, Masquelier, Bernard, Johnson, Jeffrey A., Miller, Michael D., and Kuritzkes, Daniel R.
- Subjects
DRUG resistance ,HIV ,REVERSE transcriptase inhibitors ,ANTIRETROVIRAL agents ,MICROBIAL mutation ,RESEARCH - Abstract
The article discusses a systematic review and pooled analysis of the link between preexisting drug-resistant human immunodeficiency (HIV)-1 minority variants and the risk of nonnucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral virologic failure. The risk of virologic failure was estimated using Cox proportional hazard models. There was a significant link between low-frequency HIV-1 drug resistance mutations and a higher risk of virologic failure with first-line antiretroviral treatment (ART) based on the analysis. It was found that race or ethnicity was a significant predictor of virologic failure.
- Published
- 2011
- Full Text
- View/download PDF
12. No Risk of Myocardial Infarction Associated With Initial Antiretroviral Treatment Containing Abacavir: Short and Long-Term Results from ACTG A5001/ALLRT.
- Author
-
Ribaudo, Heather J., Benson, Constance A., Zheng, Yu, Koletar, Susan L., Collier, Ann C., Lok, Judith J., Smurzynski, Marlene, Bosch, Ronald J., Bastow, Barbara, and Schouten, Jeffrey T.
- Subjects
- *
MYOCARDIAL infarction risk factors , *ANTIRETROVIRAL agents , *ABACAVIR , *CARDIOVASCULAR diseases , *HIV-positive persons , *CLINICAL trials - Abstract
In this analysis of 5056 HIV-1 infected individuals initiating randomized antiretroviral treatment in clinical trials, abacavircontaining regimens did not appear associated with increased risk of myocardial infarction (MI). Classic cardiovascular disease risk factors were the strongest predictors of MI.Background. Observational and retrospective clinical trial cohorts have reported conflicting results for the association of abacavir use with risk of myocardial infarction (MI), possibly related to issues that may bias estimation of treatment effects, such as time-varying confounders, informative dropout, and cohort loss due to competing events.Methods. We analyzed data from 5056 individuals initiating randomized antiretroviral treatment (ART) in AIDS Clinical Trials Group studies; 1704 started abacavir therapy. An intent-to-treat analysis adjusted for pretreatment covariates and weighting for informative censoring was used to estimate the hazard ratio (HR) of MIs after initiation of a regimen with or without abacavir.Results. Through 6 years after ART initiation, 36 MI events were observed in 17,404 person-years of follow-up. No evidence of an increased hazard of MI in subjects using abacavir versus no abacavir was seen (over a 1-year period: P = .50; HR, 0.7 [95% confidence interval {CI}, 0.2-2.4]); over a 6-year period: P = .24; HR, 0.6 [95% CI, 0.3-1.4]); these results were robust over as-treated and sensitivity analyses. Although the risk of MI decreased over time, there was no evidence to suggest a time-dependent abacavir effect. Classic cardiovascular disease (CVD) risk factors were the strongest predictors of MI.Conclusion. We find no evidence to suggest that initial ART containing abacavir increases MI risk over short-term and long-term periods in this population with relatively low MI risk. Traditional CVD risk factors should be the main focus in assessing CVD risk in individuals with human immunodeficiency virus infection. [ABSTRACT FROM AUTHOR]
- Published
- 2011
13. Instantaneous Inhibitory Potential Is Similar to Inhibitory Quotient at Predicting HIV-1 Response to Antiretroviral Therapy.
- Author
-
Henrich, Timothy J., Ribaudo, Heather J., and Kuritzkes, Daniel R.
- Subjects
- *
BIOCHEMISTRY , *ANTIRETROVIRAL agents , *QUANTITATIVE research , *HIV , *RNA , *CLINICAL drug trials , *REGRESSION analysis , *CLINICAL trials , *STATISTICAL correlation , *DRUG dosage , *PHARMACOKINETICS - Abstract
Background. The instantaneous inhibitory potential (IIP), a measure of antiviral activity that incorporates the slope of the dose-response curve, has been proposed as a better predictor of clinical efficacy than the inhibitory quotient (IQ). However, there are no quantitative analyses supporting this hypothesis. Methods. The correlation between differences in log10 (IQ) (Δlog (IQ)) or differences in IIP (ΔIIP) and the 10 10 differences in percentage of subjects with plasma human immunodeficiency virus type 1 (HIV-1) RNA levels <50 copies/mL at week 48 was determined for antiretroviral drugs compared in 17 randomized clinical trials. The Δlog10 (IQmin), Δlog10 (IQmax), ΔIIPmin, ΔIIPmax, Δlog10 (IQ12), Δlog10 (IQ24), ΔIIP12, and ΔIIP24 for comparative drugs were correlated with differences in percentage of subjects with HIV-1 RNA levels <50 copies/mL in each trial. log10 (IQ24), log10 (IQ12), IIP24, and IIP12 were calculated using published median effect model slope values and t½ values; r² values from linear regression and Spearman correlation coefficients were calculated for each analysis; 1/2 and correlation coefficients were compared between log10 (IQ) and IIP. Results. r² values were greatest for the Δlog10 (IQ12) and Δlog10 (IQ24) comparisons using intention-to-treat outcomes from the 17 trials. Differences in r² values between Δlog10 (IQ24) and ΔIIP24 and between Δlog10 (IQ12) and ΔIIP12 were 0.05 and 0.18, respectively. Differences in Spearman rank correlation coefficients between log10 (IQ) and IIP at each drug concentration were not significantly different, with the exception of Δlog10 (IQmax) and ΔIIPmax; the Δlog10 (IQmax) correlation was significantly stronger than the ΔIIPmax correlation. max 10 max max Conclusions. IIP was not substantially better than log (IQ) in describing the modest relationship between 10 antiviral activity, pharmacokinetics, and virologic outcomes for antiretroviral drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
14. Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure.
- Author
-
Paredes, Roger, Lalama, Christina M., Ribaudo, Heather J., Schackman, Bruce R., Shikuma, Cecilia, Giguel, Francoise, Meyer III, William A., Johnson, Victoria A., Fiscus, Susan A., D'Aquila, Richard T., Gulick, Roy M., and Kuritzkes, Daniel R.
- Subjects
ANTIRETROVIRAL agents ,HIV-positive persons ,HIGHLY active antiretroviral therapy ,HIV infections ,THERAPEUTICS ,DISEASE complications ,ANTIVIRAL agents ,POLYMERASE chain reaction ,CLINICAL trials ,CLINICAL medicine ,DISEASES - Abstract
Background. The clinical relevance of detecting minority drug-resistant human immunodeficiency virus type 1 (HIV-1) variants is uncertain. Methods. To determine the effect of pre-existing minority nonnucleoside reverse-transcriptase inhibitor (NNRTI)-resistant variants on the risk of virologic failure, we reanalyzed a case-cohort substudy of efavirenz recipients in AIDS Clinical Trials Group protocol A5095. Minority K103N or Y181C populations were determined by allele-specific polymerase chain reaction in subjects without NNRTI resistance by population sequencing. Weighted Cox proportional hazards models adjusted for recent treatment adherence estimated the relative risk of virologic failure in the presence of NNRTI-resistant minority variants. Results. The evaluable case-cohort sample included 195 subjects from the randomly selected subcohort (51 with virologic failure, 144 without virologic failure), plus 127 of the remaining subjects who experienced virologic failure. Presence of minority K103N or Y181C mutations, or both, was detected in 8 (4.4%), 54 (29.5%), and 11 (6%), respectively, of 183 evaluable subjects in the random subcohort. Detection of minority Y181C mutants was associated with an increased risk of virologic failure in the setting of recent treatment adherence (hazard ratio, 3.45 [95% confidence interval, 1.90-6.26]) but not in nonadherent subjects (hazard ratio, 1.39 [95% confidence interval, 0.58-3.29]). Of note, 70% of subjects with minority Y181C variants achieved long-term viral suppression. Conclusions. In adherent patients, pre-existing minority Y181C mutants more than tripled the risk of virologic failure of first-line efavirenz-based antiretroviral therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
15. Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1-Infected Subjects.
- Author
-
Kuritzkes, Daniel R., Lalama, Christina M., Ribaudo, Heather J., Marcial, Michelle, Meyer III, William A., Shikuma, Cecilia, Johnson, Victoria A., Fiscus, Susan A., D'Aquila, Richard T., Schackman, Bruce R., Acosta, Edward P., and Gulick, Roy M.
- Subjects
HIV ,HIV infections ,NATURAL immunity ,ANTIRETROVIRAL agents ,VIRUS disease drug therapy ,CLINICAL medicine ,VIRUS inhibitors ,PREVENTIVE medicine ,CLINICAL trials - Abstract
A case-cohort study was used to determine the effect of baseline nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance, as assessed by viral genotyping, on the response to efavirenz-containing regimens in AIDS Clinical Trials Group A5095. The sample included a random cohort of efavirenz-treated subjects plus unselected subjects who experienced virologic failure. Of 220 subjects in the random cohort, 57 (26%) had virologic failure. The prevalence of baseline NNRTI resistance was 5%. The risk of virologic failure for subjects with baseline NNRTI resistance was higher than that for subjects without such resistance (hazard ratio 2.27 [95% confidence interval], 1.15-4.49; P = .018). These results support resistance testing before starting antiretroviral therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
16. Plasma HIV-1 RNA Dynamics in Antiretroviral-Naive Subjects Receiving either Triple-Nucleoside or Efavirenz-Containing Regimens: ACTG A5166s.
- Author
-
Kuritzkes, Daniel R., Ribaudo, Heather J., Squires, Kathleen E., Koletar, Susan L., Santana, Jorge, Riddler, Sharon A., Reichman, Richard, Shikuma, Cecilia, Meyer, III, William A., Klingman, Karin L., and Gulick, Roy M.
- Subjects
- *
HIV , *ANTIRETROVIRAL agents , *DRUG efficacy , *NUCLEOSIDES , *RANDOMIZED controlled trials , *THERAPEUTICS - Abstract
Objective. We sought to compare clearance rates of plasma human immunodeficiency virus type 1 (HIV-1) RNA in men and women starting triple-nucleoside-based versus efavirenz (EFV)-based regimens. Methods. First- and second-phase decay rates of plasma HIV-1 were compared in men and women initiating a triple nucleoside reverse-transcriptase inhibitor (NRTI) regimen versus regimens that included EFV plus an NRTI. Subjects (n = 64) were randomized to receive zidovudine/lamivudine/abacavir (triple-nucleoside regimen), zidovudine/lamivudine plus EFV (3-drug EFV regimen) or zidovudine/lamivudine/abacavir plus EFV (4-drug EFV regimen). Plasma HIV-1 RNA levels were fitted to a biexponential viral-dynamics model using a nonlinear mixedeffects model. Non = arametric Wilcoxon tests compared empirical Bayes estimates of first- and second-phase viral decay rates between treatment arms and sex. Results. Median first-phase viral decay rates were significantly faster in subjects receiving the 3-drug EFV regimen (0.67/day), compared with those receiving the triple-nucleoside regimen (0.56/day; P = .02). The second-phase viral decay rate was also faster in the 3-drug EFV group than in the triple-nucleoside group (P = .09). Decay rates in the 4-drug EFV group were intermediate. Viral decay rates were not significantly different in men and women. Conclusions. Faster initial viral decay in subjects randomized to a 3-drug EFV-based regimen corresponded to the overall superior efficacy of that regimen. Viral decay rates did not differ by sex. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
17. Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-1 Infection.
- Author
-
Gulick, Roy M., Ribaudo, Heather J., Shikuma, Cecilia M., Lalama, Christina, Schackman, Bruce R., Meyer III, William A., Acosta, Edward P., Schouten, Jeffrey, Squires, Kathleen E., Pilcher, Christopher D., Murphy, Robert L., Koletar, Susan L., Carlson, Margrit, Reichman, Richard C., Bastow, Barbara, Klingman, Karin L., and Kuritzkes, Daniel R.
- Subjects
- *
ANTIRETROVIRAL agents , *CLINICAL drug trials , *HIV infections , *THERAPEUTICS , *AIDS treatment , *VIRUS research , *RANDOMIZED controlled trials , *MEDICAL research - Abstract
Context Three-drug antiretroviral regimens are standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a 4-drug regimen could improve antiretroviral activity and be more effective than a 3-drug regimen. Objective To compare the safety/efficacy of 3-drug vs 4-drug regimens for initial treatment of HIV-1 infection. Design The AIDS Clinical Trials Group (ACTG) A5095 study, a randomized, double- blind, placebo-controlled study with enrollment and follow-up conducted from March 22,2001, to March 1,2005, and enrolling treatment-naive, HIV-1-infected patients with HIV-1 RNA levels of 400 copies/mL or greater from US clinical trials units of the ACTG. Interventions Zidovudine/lamivudine plus efavirenz (3-drug regimen) vs zidovudine/lamivudine/abacavir plus efavirenz (4-drug regimen). Main Outcome Measures Time to virologic failure (defined as time to first of 2 successive HIV-1 RNA levels ≥200 copies/mL at or after week 16), CD4 cell count changes, and grade 3 or 4 adverse events. HIV-1 RNA data were intent-to-treat, regardless of treatment changes. Results Seven hundred sixty-five patients with a baseline mean HIV-1 RNA level of 4.86 log10 (72 444) copies/mL and CD4 cell count of 240 cells/mm3 were randomized. After a median 3-year follow-up, 99 (26%) of 382 and 94 (25%) of 383 patients receiving the 3-drug and 4-drug regimens, respectively, reached protocol-defined virologic failure; time to virologic failure was not significantly different (hazard ratio, 0.95; 97.5% confidence interval, 0.69-1.33; P= .73). In planned subgroup analyses, increased risk for virologic failure was seen in non-Hispanic black patients (adjusted hazard ratio, 1.66; 95% confidence interval, 1.18-2.34; P=.003). At 3 years, the HIV-1 RNA level was less than 200 copies/mL in 152 (90%) of 169 and 143 (92%) of 156 patients receiving the 3-drug and 4-drug regimens, respectively (P=.59), and less than 50 copies/mL in 144 (85%) of 169 and 137 (88%) of 156 patients (P=.39). CD4 cell count increases and grade 3 or 4 adverse events were not significantly different. Conclusions In treatment-naive patients, there were no significant differences between the 3-drug and 4-drug antiretroviral regimens; overall, at least approximately 80% of patients had HIV-1 RNA levels less than 50 copies/mL through 3 years. These results support current guidelines recommending 2 nucleosides plus efavirenz for initial treatment of HIV-1 infection; adding abacavir as a fourth drug provided no additional benefit. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
18. Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.
- Author
-
Fichtenbaum, Carl J, Ribaudo, Heather J, Leon-Cruz, Jorge, Overton, Edgar T, Zanni, Markella V, Malvestutto, Carlos D, Aberg, Judith A, Kileel, Emma M, Fitch, Kathleen V, Schalkwyk, Marije Van, Kumarasamy, Nagalingeswaran, Martinez, Esteban, Santos, Breno Riegel, Joseph, Yvetot, Lo, Janet, Siminski, Sue, Melbourne, Kathleen, Sponseller, Craig A, Desvigne-Nickens, Patrice, and Bloomfield, Gerald S
- Subjects
- *
ANTIRETROVIRAL agents - Published
- 2021
- Full Text
- View/download PDF
19. Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection.
- Author
-
Gulick, Roy M., Ribaudo, Heather J., Shikuma, Cecilia M., Lustgarten, Stephanie, Squires, Kathleen E., Meyer, William A., Acosta, Edward P., Schackman, Bruce R., Pilcher, Christopher D., Murphy, Robert L., Maher, William E., Witt, Mallory D., Reichman, Richard C., Snyder, Sally, Klingman, Karin L., and Kuritzkes, Daniel R.
- Subjects
- *
CLINICAL trials , *THERAPEUTICS , *HIV infections , *NUCLEOSIDES , *VIRAL disease treatment , *ANTIRETROVIRAL agents , *DRUG resistance , *HEALTH outcome assessment - Abstract
Background: Regimens containing three nucleoside reverse-transcriptase inhibitors offer an alternative to regimens containing nonnucleoside reverse-transcriptase inhibitors or protease inhibitors for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection, but data from direct comparisons are limited. Methods: This randomized, double-blind study involved three antiretroviral regimens for the initial treatment of subjects infected with HIV-1: zidovudine–lamivudine–abacavir, zidovudine–lamivudine plus efavirenz, and zidovudine–lamivudine–abacavir plus efavirenz. REsults We enrolled a total of 1147 subjects with a mean baseline HIV-1 RNA level of 4.85 log10 (71,434) copies per milliliter and a mean CD4 cell count of 238 per cubic millimeter were enrolled. A scheduled review by the data and safety monitoring board with the use of prespecified stopping boundaries led to a recommendation to stop the triple-nucleoside group and to present the results in the triple-nucleoside group in comparison with pooled data from the efavirenz groups. After a median follow-up of 32 weeks, 82 of 382 subjects in the triple-nucleoside group (21 percent) and 85 of 765 of those in the combined efavirenz groups (11 percent) had virologic failure; the time to virologic failure was significantly shorter in the triple-nucleoside group (P<0.001). This difference was observed regardless of the pretreatment HIV-1 RNA stratum (at least 100,000 copies per milliliter or below this level; P≤0.001 for both comparisons). Changes in the CD4 cell count and the incidence of grade 3 or grade 4 adverse events did not differ significantly between the groups. Conclusions: In this trial of the initial treatment of HIV-1 infection, the triple-nucleoside combination of abacavir, zidovudine, and lamivudine was virologically inferior to a regimen containing efavirenz and two or three nucleosides. N Engl J Med 2004;350:1850-61. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
20. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.
- Author
-
Grinsztejn, Beatriz, Hosseinipour, Mina C, Ribaudo, Heather J, Swindells, Susan, Eron, Joseph, Chen, Ying Q, Wang, Lei, Ou, San-San, Anderson, Maija, McCauley, Marybeth, Gamble, Theresa, Kumarasamy, Nagalingeshwaran, Hakim, James G, Kumwenda, Johnstone, Pilotto, Jose H S, Godbole, Sheela V, Chariyalertsak, Suwat, de Melo, Marineide Gonçalves, Mayer, Kenneth H, and Eshleman, Susan H
- Subjects
- *
ANTIRETROVIRAL agents , *HIV infections , *THERAPEUTICS , *RANDOMIZED controlled trials , *MORTALITY of AIDS patients , *HEALTH outcome assessment , *DISEASE progression , *CLINICAL trials - Abstract
Summary: Background: Use of antiretroviral treatment for HIV-1 infection has decreased AIDS-related morbidity and mortality and prevents sexual transmission of HIV-1. However, the best time to initiate antiretroviral treatment to reduce progression of HIV-1 infection or non-AIDS clinical events is unknown. We reported previously that early antiretroviral treatment reduced HIV-1 transmission by 96%. We aimed to compare the effects of early and delayed initiation of antiretroviral treatment on clinical outcomes. Methods: The HPTN 052 trial is a randomised controlled trial done at 13 sites in nine countries. We enrolled HIV-1-serodiscordant couples to the study and randomly allocated them to either early or delayed antiretroviral treatment by use of permuted block randomisation, stratified by site. Random assignment was unblinded. The HIV-1-infected member of every couple initiated antiretroviral treatment either on entry into the study (early treatment group) or after a decline in CD4 count or with onset of an AIDS-related illness (delayed treatment group). Primary events were AIDS clinical events (WHO stage 4 HIV-1 disease, tuberculosis, and severe bacterial infections) and the following serious medical conditions unrelated to AIDS: serious cardiovascular or vascular disease, serious liver disease, end-stage renal disease, new-onset diabetes mellitus, and non-AIDS malignant disease. Analysis was by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT00074581. Findings: 1763 people with HIV-1 infection and a serodiscordant partner were enrolled in the study; 886 were assigned early antiretroviral treatment and 877 to the delayed treatment group (two individuals were excluded from this group after randomisation). Median CD4 counts at randomisation were 442 (IQR 373–522) cells per μL in patients assigned to the early treatment group and 428 (357–522) cells per μL in those allocated delayed antiretroviral treatment. In the delayed group, antiretroviral treatment was initiated at a median CD4 count of 230 (IQR 197–249) cells per μL. Primary clinical events were reported in 57 individuals assigned to early treatment initiation versus 77 people allocated to delayed antiretroviral treatment (hazard ratio 0·73, 95% CI 0·52–1·03; p=0·074). New-onset AIDS events were recorded in 40 participants assigned to early antiretroviral treatment versus 61 allocated delayed initiation (0·64, 0·43–0·96; p=0·031), tuberculosis developed in 17 versus 34 patients, respectively (0·49, 0·28–0·89, p=0·018), and primary non-AIDS events were rare (12 in the early group vs nine with delayed treatment). In total, 498 primary and secondary outcomes occurred in the early treatment group (incidence 24·9 per 100 person-years, 95% CI 22·5–27·5) versus 585 in the delayed treatment group (29·2 per 100 person-years, 26·5–32·1; p=0·025). 26 people died, 11 who were allocated to early antiretroviral treatment and 15 who were assigned to the delayed treatment group. Interpretation: Early initiation of antiretroviral treatment delayed the time to AIDS events and decreased the incidence of primary and secondary outcomes. The clinical benefits recorded, combined with the striking reduction in HIV-1 transmission risk previously reported, provides strong support for earlier initiation of antiretroviral treatment. Funding: US National Institute of Allergy and Infectious Diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
21. Metabolic Effects of Protease Inhibitor—Sparing Anti retroviral Regimens Given as InitialTreatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
- Author
-
Shikuma, Cecilia M., Yang Yang, Glesby, Marshall J., Meyer, William A., Tashima, Karen T., Ribaudo, Heather J., Webb, Nancy, Bastow, Barbara, Kuritzkes, Daniel R., and Gulick, Roy M.
- Subjects
- *
METABOLISM , *PROTEASE inhibitors , *HIV infections , *THERAPEUTICS , *ANTIRETROVIRAL agents , *CLINICAL trials , *NUCLEOSIDES - Abstract
The article assesses the metabolic changes after initiation of protease inhibitor-sparing regimens in antiretroviral-naive patients. Metabolic changes were analyzed within the triple-nucleoside-containing, three-drug efavirenz-containing, and four-drug efavirenz-containing arms of the AIDS Clinical Trials Group multicenter trial A5095.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.